The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Induction of potent antitumor immunity by in situ targeting of intratumoral DCs
Abstract
Recent reports of tumor regression following delivery of autologous tumor antigen-pulsed DCs suggest that defective antigen presentation may play a key role in tumor escape. Here we show in two different murine tumor models, CT26 (colon adenocarcinoma) and B16 (melanoma), that the number and activation state of intratumoral DCs are critical factors in the host response to tumors. We used CCL20/macrophage inflammatory protein-3alpha (MIP-3alpha) chemokine to increase the number of tumoral DCs and intratumoral injections of CG-rich motifs (CpGs) to activate such cells. Expression of CCL20 in the tumor site attracted large numbers of circulating DCs into the tumor mass and, in the case of CT26 tumors, led to complete tumor regression. Intratumoral CpG injections, in addition to CCL20, were required to induce therapeutic immunity against B16 tumors. In this model CpG overcame tumor-mediated inhibition of DC activation and enabled tumoral DCs to cross-present tumor antigens to naive CD8 T cells. CpG activation of tumoral DCs alone was not sufficient to induce tumor regression in either tumor model, nor was systemic delivery of the DC growth factor, Flt3 ligand, which dramatically increased the number of circulating DCs but not the number of tumoral DCs. These results indicate that the number of tumoral DCs as well as the tumor milieu determines the ability of tumor-bearing hosts to mount an effective antitumor immune response. Our results also suggest that DCs can be manipulated in vivo without delivery of defined tumor antigens to induce a specific T cell-mediated antitumor response and provide the basis for the use of chemokines in DC-targeted clinical strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Menetrier-Caux, C., Montmain, G., Dieu, M. C., Bain, C., Favrot, M. C., Caux, C., & Blay, J. Y. (1998) · Blood · doi:10.1182/blood.v92.12.4778 · Cited by 590
Bell, D., Chomarat, P., Broyles, D., Netto, G., Harb, G. M., Lebecque, S., Valladeau, J., Davoust, J., Palucka, K. A., & Banchereau, J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1417 · Cited by 544
Vicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020732 · Cited by 343
Research works printed but not linked: 43
- 10.1038/32588 · DOI · Paper page
- 10.1146/annurev.immunol.18.1.767 · DOI · Paper page
- 10.1038/nm1096-1096 · DOI · Paper page
- Gabrilovich, 1997, Clin. Cancer Res., 3, 483
- Nestle, 1997, Am. J. Pathol., 150, 641
- 10.1006/scbi.2001.0400 · DOI · Paper page
- 10.1002/path.1344 · DOI · Paper page
- 10.1146/annurev.immunol.18.1.245 · DOI · Paper page
- 10.1084/jem.193.2.233 · DOI · Paper page
- 10.1182/blood.V99.5.1676 · DOI
- 10.1038/nm882 · DOI
- 10.1007/s002810000053 · DOI · Paper page
- 10.1126/science.286.5447.2098 · DOI · Paper page
- 10.1084/jem.189.3.447 · DOI · Paper page
- 10.1016/0092-8674(94)90169-4 · DOI · Paper page
- 10.1038/353180a0 · DOI · Paper page
- 10.1016/0092-8674(91)90462-8 · DOI · Paper page
- 10.1038/nm1295-1297 · DOI · Paper page
- McKenna, 1995, Blood., 86, 3413, 10.1182/blood.V86.9.3413.bloodjournal8693413 · DOI
- 10.1084/jem.184.5.1953 · DOI · Paper page
- 10.1074/jbc.272.9.5846 · DOI · Paper page
- 10.1074/jbc.272.23.14893 · DOI · Paper page
- 10.1016/S0014-5793(98)01450-1 · DOI
- 10.1084/jem.188.2.373 · DOI · Paper page
- Liao, 1999, J. Immunol., 162, 186, 10.4049/jimmunol.162.1.186 · DOI · Paper page
- 10.1084/jem.191.8.1303 · DOI · Paper page
- 10.1002/1521-4141(200201)32:1<104::AID-IMMU104>3.0.CO;2-C · DOI
- Liao, 2002, J. Immunol., 168, 4871, 10.4049/jimmunol.168.10.4871 · DOI
- 10.1084/jem.191.8.1381 · DOI · Paper page
- 10.1172/JCI7548 · DOI · Paper page
- 10.1046/j.1365-2567.2000.00964.x · DOI
- Datta, 2003, J. Immunol., 170, 4102, 10.4049/jimmunol.170.8.4102 · DOI · Paper page
- 10.1002/1521-4141(200012)30:12<3591::AID-IMMU3591>3.0.CO;2-J · DOI · Paper page
- 10.1038/75365 · DOI · Paper page
- Steinbrink, 1997, J. Immunol., 159, 4772, 10.4049/jimmunol.159.10.4772 · DOI · Paper page
- 10.1146/annurev.immunol.16.1.137 · DOI · Paper page
- Kawarada, 2001, J. Immunol., 167, 5247, 10.4049/jimmunol.167.9.5247 · DOI · Paper page
- Ballas, 2001, J. Immunol., 167, 4878, 10.4049/jimmunol.167.9.4878 · DOI · Paper page
- Vicari, 2000, J. Immunol., 165, 1992, 10.4049/jimmunol.165.4.1992 · DOI
- Salcedo, 2000, Blood., 96, 34, 10.1182/blood.V96.1.34 · DOI · Paper page
- 10.1038/nm0697-625 · DOI · Paper page
- 10.1002/(SICI)1097-0215(20000615)86:6<827::AID-IJC11>3.0.CO;2-R · doi:10.1002/(sici)1097-0215(20000615)86:6<827::aid-ijc11>3.0.co;2-r
- Chen, 1997, Cancer Res., 57, 3511
Cited by
Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852
T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X. O., Yamazaki, T., Lu, S., Hwu, P., Restifo, N. P., Overwijk, W. W., & Dong, C. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.014 · Cited by 800
Key chemokines direct migration of immune cells in solid tumors
Kohli, K., Pillarisetty, V. G., & Kim, T. S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00303-x · Cited by 583
Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4262 · Cited by 549
Toll-Like Receptors on Tumor Cells Facilitate Evasion of Immune Surveillance
Huang, B., Zhao, J., Li, H., He, K.-L., Chen, Y., Mayer, L., Unkeless, J. C., & Xiong, H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0784 · Cited by 542
Metadata
- Authors
- Furumoto, K., Soares, L., Engleman, E. G., & Merad, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-03-01
- Volume
- 113
- Issue
- 5
- Pages
- 774-783
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2165123753
- Cited by
- 184
- References
- 3
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. https://app.cochat.ai/papers/10.1172/jci19762
- The paper
- Furumoto, K., Soares, L., Engleman, E. G., & Merad, M. (2004). Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. Journal of Clinical Investigation. https://doi.org/10.1172/jci19762
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.